193 related articles for article (PubMed ID: 23678596)
1. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
2. Profile of blonanserin for the treatment of schizophrenia.
Tenjin T; Miyamoto S; Ninomiya Y; Kitajima R; Ogino S; Miyake N; Yamaguchi N
Neuropsychiatr Dis Treat; 2013; 9():587-94. PubMed ID: 23766647
[TBL] [Abstract][Full Text] [Related]
3. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
5. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
6. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Takahashi S; Suzuki M; Uchiyama M
Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
[TBL] [Abstract][Full Text] [Related]
8. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
Takaki M; Ujike H
Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.
Suzuki H; Gen K
Psychiatry Clin Neurosci; 2012 Mar; 66(2):146-52. PubMed ID: 22353327
[TBL] [Abstract][Full Text] [Related]
10. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Harvey PD; Nakamura H; Murasaki M
Neuropsychopharmacol Rep; 2019 Sep; 39(3):173-182. PubMed ID: 31041855
[TBL] [Abstract][Full Text] [Related]
11. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
12. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
[TBL] [Abstract][Full Text] [Related]
14. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of risperidone on positive features of schizophrenia.
McEvoy JP
J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
[TBL] [Abstract][Full Text] [Related]
16. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Tenjin T; Miyamoto S; Miyake N; Ogino S; Kitajima R; Ojima K; Arai J; Teramoto H; Tsukahara S; Ito Y; Tadokoro M; Anai K; Funamoto Y; Kaneda Y; Sumiyoshi T; Yamaguchi N
Hum Psychopharmacol; 2012 Jan; 27(1):90-100. PubMed ID: 22278973
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
18. Risperidone.
Cohen LJ
Pharmacotherapy; 1994; 14(3):253-65. PubMed ID: 7524043
[TBL] [Abstract][Full Text] [Related]
19. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Harvey PD; Nakamura H; Miura S
Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
[TBL] [Abstract][Full Text] [Related]
20. Three cases of schizophrenia showing improvement after switching to blonanserin.
Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
[No Abstract] [Full Text] [Related]
[Next] [New Search]